Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response

Abstract

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This patent application is a continuation-in-part of U.S. application Ser. No. 10 / 400,293, filed Mar. 26, 2003, and a continuation-in-part of U.S. application Ser. No. 10 / 401,283, filed Mar. 26, 2003, both of which claim the benefit under 35 U.S.C. § 119(e) to provisional application No. 60 / 450,237, filed on Feb. 25, 2003, and provisional application No. 60 / 420,383, filed on Oct. 21, 2002. The contents of each of these earlier applications are hereby incorporated by reference as if recited herein in their entirety.[0003] BACKGROUND OF THE INVENTION [0004] 1. Field of the Invention [0005] The present invention relates generally to synergistic compositions that treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and to methods of modulating inflammation in cells. More specifically, the invention relates to composition comprising a fraction isolated or derived from hops along with a sy...

AI Technical Summary

Benefits of technology

[0035] Preferred embodiments further provides a composition to increase the rate at which glucosamine or chondrotin sulfate finction to normalize joint movement or reduce the symptoms of osteoarthritis.

[0036] Preferred embodiments also provide for methods of identifying compositions that would specifically inhibit or prevent the synthesis of prostaglandins by COX-2 in inflammatory cells with little or no effect on PGE2 synthesis in gastric mucosal cells.

Problems solved by technology

COX-1 and COX-2, however, may generate a unique pattern and variable amounts of eicosanoids; therefore, relative differences in the activation of these isozymes may result in quite dissimilar biological responses.

However, conventional non-steroidal anti-inflammatory drugs lack the specificity of inhibiting COX-2 without affecting gastric PGE2 synthesis and are at risk to cause damages on the gastrointestinal system, when used for extended periods.

Indeed, even the newly developed, anti-inflammatory drugs such as rofecoxib and celexocib produce untoward gastric toxicity in the form of induced spontaneous bleeding and delay of gastric ulcer healing.

However, while the implication is that such a calculated selectivity will result in lower gastric irritancy, unless the test materials are evaluated in gastric cells, the term “selective COX-2 inhibitor” does not carry assurance of safety to gastrointestinal cells.

The major problem associated with ascertaining COX-2 selectivity (i.e. low gastric irritancy) is that differences in assay methodology can have profound effects on the results obtained.

Generally, models using human cell lines or human platelets and monocytes are the current standard and validated target cell models have not been forthcoming.

Finally, the protein concentration of the medium can vary; this is an issue for compounds that can bind avidly to plasma proteins.

No laboratory has, as yet, developed an ideal assay for COX-2 selectivity.

Images